aprocitentan (Tryvio)
Jump to navigation
Jump to search
Indications
- treatment-resistant hypertension in combination with other antihypertensives
Contraindications
- pregnancy: embryo-fetal toxicity
- breast feeding not advised
Dosage
Adverse effects
Mechanism of action
Notes
- prescribers must certify with the Tryvio Risk Evaluation & Mitigation Strategy program owing to the risk for embryo-fetal toxicity
More general terms
References
- ↑ 1.0 1.1 1.2 Brooks M FDA Okays New Drug for Resistant Hypertension. Medscape. March 20, 2024 https://www.medscape.com/viewarticle/fda-okays-new-drug-resistant-hypertension-2024a100058b
- ↑ 2.0 2.1 Approved Tryvio label. Highlights of Prescribing Information TRYVIO <TM> (aprocitentan) tablets, for oral use U.S. Food and Drug Administration; 2024 Mar 19. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217686s000lbl.pdf